PL2279206T3 - Metoda zapobiegania rozwojowi reumatoidalnego zapalenia stawów u osób z niezróżnicowanym zapaleniem stawów - Google Patents

Metoda zapobiegania rozwojowi reumatoidalnego zapalenia stawów u osób z niezróżnicowanym zapaleniem stawów

Info

Publication number
PL2279206T3
PL2279206T3 PL09743410T PL09743410T PL2279206T3 PL 2279206 T3 PL2279206 T3 PL 2279206T3 PL 09743410 T PL09743410 T PL 09743410T PL 09743410 T PL09743410 T PL 09743410T PL 2279206 T3 PL2279206 T3 PL 2279206T3
Authority
PL
Poland
Prior art keywords
arthritis
subjects
development
preventing
undifferentiated
Prior art date
Application number
PL09743410T
Other languages
English (en)
Inventor
George Vratsanos
Jean-Claude Becker
Michael Corbo
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41264941&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2279206(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PL2279206T3 publication Critical patent/PL2279206T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
PL09743410T 2008-05-05 2009-05-05 Metoda zapobiegania rozwojowi reumatoidalnego zapalenia stawów u osób z niezróżnicowanym zapaleniem stawów PL2279206T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US5033608P 2008-05-05 2008-05-05
US12/387,359 US7915222B2 (en) 2008-05-05 2009-05-01 Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
PCT/US2009/042761 WO2009137424A1 (en) 2008-05-05 2009-05-05 Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
EP20090743410 EP2279206B1 (en) 2008-05-05 2009-05-05 Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis

Publications (1)

Publication Number Publication Date
PL2279206T3 true PL2279206T3 (pl) 2015-09-30

Family

ID=41264941

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09743410T PL2279206T3 (pl) 2008-05-05 2009-05-05 Metoda zapobiegania rozwojowi reumatoidalnego zapalenia stawów u osób z niezróżnicowanym zapaleniem stawów

Country Status (25)

Country Link
US (3) US7915222B2 (pl)
EP (2) EP2891665A1 (pl)
JP (1) JP2011522795A (pl)
KR (1) KR20110014180A (pl)
CN (1) CN102037010A (pl)
AR (1) AR071672A1 (pl)
AU (1) AU2009244448B2 (pl)
BR (1) BRPI0912249A2 (pl)
CA (1) CA2723698C (pl)
CL (1) CL2009001082A1 (pl)
DK (1) DK2279206T3 (pl)
EA (1) EA201001749A1 (pl)
ES (1) ES2539840T3 (pl)
HK (1) HK1208230A1 (pl)
HR (1) HRP20150552T1 (pl)
HU (1) HUE025256T2 (pl)
IL (1) IL208691A (pl)
MX (1) MX2010011503A (pl)
NZ (1) NZ589020A (pl)
PL (1) PL2279206T3 (pl)
PT (1) PT2279206E (pl)
SI (1) SI2279206T1 (pl)
TW (2) TW201444575A (pl)
WO (1) WO2009137424A1 (pl)
ZA (1) ZA201007914B (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040022787A1 (en) * 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
US7915222B2 (en) 2008-05-05 2011-03-29 Bristol-Myers Squibb Company Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
US20140335081A1 (en) * 2011-10-10 2014-11-13 Medlmmune Limited Treatment For Rheumatoid Arthritis
US20140006055A1 (en) * 2012-06-27 2014-01-02 Iagnosis, Inc. Integrated Medical Evaluation and Record Keeping System
EP2914292A4 (en) * 2012-10-30 2016-05-04 Univ Emory Stimulation of bone formation by inhibition of CD28-co-stimulation
WO2014151230A2 (en) * 2013-03-15 2014-09-25 Bristol-Myers Squibb Company Method of treating granulomatosis with polyangiitis
AU2015249656A1 (en) * 2014-04-25 2016-11-03 Bristol-Myers Squibb Company Use of CTLA4 compound for achieving drug-free remission in subjects with early RA
PT3283508T (pt) 2015-04-17 2021-06-21 Alpine Immune Sciences Inc Proteínas imuno modulatórias com afinidades afináveis
CA3077509A1 (en) 2017-10-10 2019-04-18 Alpine Immune Sciences, Inc. Ctla-4 variant immunomodulatory proteins and uses thereof
AU2019205273B2 (en) 2018-01-03 2024-04-04 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof
CN110148465B (zh) * 2019-05-10 2023-07-04 中山大学孙逸仙纪念医院 一种用于分析类风湿性关节炎的系统

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6641809B1 (en) * 1990-03-26 2003-11-04 Bristol-Myers Squibb Company Method of regulating cellular processes mediated by B7 and CD28
US7070776B1 (en) * 1990-03-26 2006-07-04 Bristol-Myers Squibb Company Methods for blocking binding of CD28 receptor to B7
US6090914A (en) * 1991-06-27 2000-07-18 Bristol-Myers Squibb Company CTLA4/CD28Ig hybrid fusion proteins and uses thereof
US5844095A (en) * 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US5770197A (en) * 1991-06-27 1998-06-23 Bristol-Myers Squibb Company Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
US5851795A (en) * 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
ES2123001T5 (es) * 1991-06-27 2009-04-16 Bristol-Myers Squibb Company Receptor ctl4a, proteinas de fusion que lo contienen y sus usos.
AU692435B2 (en) * 1993-01-21 1998-06-11 United States Of America, As Represented By The Secretary Of Agriculture, The Vaccines and methods for preventing and treating fescue toxicosis in herbivo res
US5773253A (en) * 1993-01-22 1998-06-30 Bristol-Myers Squibb Company MYPPPY variants of CTL A4 and uses thereof
US6750334B1 (en) * 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
PT892643E (pt) * 1996-03-20 2002-09-30 Univ Emory Metodos para inibir uma resposta imunitaria bloqueando os circuitos de gp39/cd40 e ctla4/cd28/b7 e composicoes utilizaveis para o efeito
US20030219863A1 (en) * 1997-01-31 2003-11-27 Bristol-Myers Squibb Company Soluble CTLA4 mutant molecules and uses thereof
ZA98533B (en) * 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
US7094874B2 (en) * 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
MXPA02012157A (es) * 2000-06-09 2003-06-06 Bristol Myers Squibb Co Metodos para regular una respuesta inmune mediada por celulas al bloquear se°ales linfociticas y al bloquear la adhesion mediada por el antigeno 1 asociado con la funcion de linfocitos.
US20040022787A1 (en) * 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
PL212205B1 (pl) * 2000-07-03 2012-08-31 Bristol Myers Squibb Co Zastosowanie rozpuszczalnej zmutowanej cząsteczki CTLA4
AU2002243905B2 (en) * 2001-01-26 2007-11-08 Emory University Methods of inducing organ transplant tolerance and correcting hemoglobinopathies
PL204899B1 (pl) * 2001-05-23 2010-02-26 Bristol Myers Squibb Co Zastosowanie rozpuszczalnej zmutowanej cząsteczki CTLA4
TWI312368B (en) * 2002-12-23 2009-07-21 Bristol Myers Squibb Compan Mammalian cell culture processes for protein production
SI1576182T2 (sl) * 2002-12-23 2020-07-31 Bristol-Myers Squibb Company Izboljšava kvalitete izdelka v procesih pridelave beljakovin v celični kulturi sesalcev
CA2762015A1 (en) * 2003-08-04 2005-02-24 Bristol-Myers Squibb Company Methods for treating cardiovascular disease using a soluble ctla4 molecule
MX2007016203A (es) 2005-06-29 2008-03-10 Compumedics Ltd Ensamble de sensor con puente conductivo.
WO2007024964A1 (en) * 2005-08-22 2007-03-01 Incept, Llc Flared stents and apparatus and methods for making and using them
KR101378194B1 (ko) 2005-12-20 2014-03-27 브리스톨-마이어스 스큅 컴퍼니 안정한 단백질 제제
JP5096369B2 (ja) 2005-12-20 2012-12-12 ブリストル−マイヤーズ スクイブ カンパニー 組成物および組成物の製造方法
US7528111B2 (en) * 2006-05-12 2009-05-05 Bristol-Myers Squibb Company Method of vaccinating subjects receiving immune modulating therapy
US7915222B2 (en) * 2008-05-05 2011-03-29 Bristol-Myers Squibb Company Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis

Also Published As

Publication number Publication date
IL208691A (en) 2015-01-29
IL208691A0 (en) 2010-12-30
CA2723698A1 (en) 2009-11-12
US8435952B2 (en) 2013-05-07
US20090280119A1 (en) 2009-11-12
AU2009244448A1 (en) 2009-11-12
TW201444575A (zh) 2014-12-01
KR20110014180A (ko) 2011-02-10
WO2009137424A1 (en) 2009-11-12
HK1148291A1 (en) 2011-09-02
US9012408B2 (en) 2015-04-21
EP2279206A1 (en) 2011-02-02
TW200948381A (en) 2009-12-01
EA201001749A1 (ru) 2011-06-30
CA2723698C (en) 2018-03-06
SI2279206T1 (sl) 2015-08-31
CL2009001082A1 (es) 2010-02-12
AR071672A1 (es) 2010-07-07
HRP20150552T1 (hr) 2015-06-19
ES2539840T3 (es) 2015-07-06
MX2010011503A (es) 2010-11-09
TWI454278B (zh) 2014-10-01
AU2009244448B2 (en) 2014-07-31
CN102037010A (zh) 2011-04-27
HUE025256T2 (en) 2016-02-29
BRPI0912249A2 (pt) 2015-10-20
JP2011522795A (ja) 2011-08-04
DK2279206T3 (en) 2015-07-27
HK1208230A1 (en) 2016-02-26
US20110142835A1 (en) 2011-06-16
EP2891665A1 (en) 2015-07-08
EP2279206B1 (en) 2015-04-22
ZA201007914B (en) 2011-07-27
PT2279206E (pt) 2015-07-27
US20130195865A1 (en) 2013-08-01
EP2279206A4 (en) 2011-05-25
NZ589020A (en) 2012-05-25
US7915222B2 (en) 2011-03-29

Similar Documents

Publication Publication Date Title
IL208691A0 (en) Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
IL244197A0 (en) Antibodies against cd100 and methods of using them
EP2508487A4 (en) WASTEWATER PRETREATMENT METHOD AND EFFLUENT TREATMENT METHOD USING THE PRETREATMENT PROCESS
IL250624B (en) Anti-fgfr3 antibodies and methods of using them
EP2262038A4 (en) Cell selector and cell with it
PL4203130T3 (pl) Separator i urządzenie elektrochemiczne mające taki separator
EP2164981A4 (en) METHODS AND DEVICES FOR DETERMINING ANALYTES
PT3281952T (pt) Um antigénio associado a artrite reumatoide
PL2394156T3 (pl) Układ i sposób do pomiaru elektrochemicznego reakcji biochemicznych jak też sposób wytworzenia takiego układu
EP2343759A4 (en) BATTERY COMPONENT AND BATTERY
AP2011005536A0 (en) Treatment of rheumatoid arthritis with mammal betadefensins.
IL219136A0 (en) Anti-hepsin antibodies and methods using same
GB0903151D0 (en) Antibody uses and methods
FI20095020L (fi) Menetelmä aukirullaimen yhteydessä
IL216389A0 (en) Solar field and method for assembling the solar field
TWI372256B (en) Test apparature and test method
GB0822140D0 (en) Methods and reagents
PL2103942T3 (pl) Sposób określania charakteru zapalnej choroby reumatycznej w płynie maziowym
GB0707069D0 (en) Methods and uses
TWI373159B (en) Electrolyte for electrochemical device and the electrochemical device thereof
EP2185685A4 (en) NEW PROCESSES AND NEW CELL LINES
GB0810609D0 (en) Methods and uses
GB0816523D0 (en) Methods and uses
GB0819611D0 (en) Electrochemical cells and components thereof
PL385706A1 (pl) System komputerowy i sposób korzystania z komputera